LISINOPRIL TABLET

Pays: Canada

Langue: anglais

Source: Health Canada

Ingrédients actifs:

LISINOPRIL

Disponible depuis:

SIVEM PHARMACEUTICALS ULC

Code ATC:

C09AA03

DCI (Dénomination commune internationale):

LISINOPRIL

Dosage:

40MG

forme pharmaceutique:

TABLET

Composition:

LISINOPRIL 40MG

Mode d'administration:

ORAL

Unités en paquet:

100

Type d'ordonnance:

Prescription

Domaine thérapeutique:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Descriptif du produit:

Active ingredient group (AIG) number: 0121550004; AHFS:

Statut de autorisation:

CANCELLED PRE MARKET

Date de l'autorisation:

2022-05-27

Résumé des caractéristiques du produit

_LISINOPRIL Product Monograph Page 1 of 41 _
1
PRODUCT MONOGRAPH
PR
LISINOPRIL
(lisinopril tablets USP)
Tablets 5 mg, 10 mg, 20 mg and 40 mg
ANGIOTENSIN CONVERTING ENZYME INHIBITOR
Sivem Pharmaceuticals ULC
4705 Dobrin Street
Saint-Laurent, Quebec
H4R 2P7
Date of Revision:
February 1, 2018
www.sivem.ca Control No.: 212867
_ _
_LISINOPRIL Product Monograph Page 2 of 41 _
PRODUCT MONOGRAPH
PR
LISINOPRIL
(lisinopril tablets USP)
Tablets 5 mg, 10 mg, 20 mg and 40 mg
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which
is used in the treatment of
hypertension, congestive heart failure and following myocardial
infarction in hemodynamically
stable patients.
ACE is a peptidyl dipeptidase which catalyzes the conversion of
angiotensin I to the pressor
substance, angiotensin II. Inhibition of ACE results in decreased
plasma angiotensin II, which
leads to increased plasma renin activity (due to removal of negative
feedback of renin release)
and decreased aldosterone secretion. Although the latter decrease is
small, it results in a small
increase in serum potassium. In patients treated with lisinopril and a
thiazide diuretic there was
essentially no change in serum potassium (see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of lisinopril
is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system (RAAS),
lisinopril also lowers blood
pressure in patients with low-renin hypertension.
PHARMACODYNAMICS
Hypertension
_Adults:_ Administration of lisinopril to patients with hypertension
results in a reduction of both
supine and standing blood pressure. Abrupt withdrawal of lisinopril
has not been associated with
a rapid increase in blood pressure. In most patients studied, after
oral adm